The Lyfebulb-Novo Nordisk Innovation Summit 2017 will recognize and empower international Patient Entrepreneurs with big ideas that disrupt the future of diabetes management

6-8 November, 2017 / Copenhagen, Denmark

Applications Closed

2017 Award Recipient

Amin Zayani

CEO & Co-Founder at Med Angel BV

About Amin Zayani

Amin lives with T1D since 2006, he is a solar energy engineer by training and a hardware expert by trade. After a frustrating accident in 2013, when his insulin was frozen in the domestic refrigerator, he became discovered a massive flaw in the way medications are stored and handled at home, and decided to found MedAngel to solve this problem. He is currently leading a team of engineers, pharmacists and designers to revolutionise the interaction patient-medication, and bring peace of mind to everyone.

The Finalists

The Summit

The Innovation Summit will bring together Patient Entrepreneurs with venture capitalists, Lyfebulb founders, Novo Nordisk Device R&D leadership, researchers and engineers, in order to spotlight entrepreneurs’ efforts and ideas, and provide professional discussion, direction, and inspiration.


  • Innovation Award
  • Keynotes
  • Workshops & Discussions
  • The Future Rooms Experience

The Jury

The Award

Patient Entrepreneurs have a unique ability to create value-adding disease management solutions beyond therapy. Our aim is to support patient-driven innovation and laser-focus on improving the quality of life for those living with diabetes.



The pitch competition brings to the stage emerging Patient Entrepreneurs to pitch their invention or idea to Lyfebulb founders, Novo Nordisk R&D device leadership, researchers and engineers, and venture capitalists. Contestants will respond to a round of Q&A by the judging panel. The top three outstanding Patient Entrepreneurs will receive monetary awards to further develop their ideas:

  • 1st Prize: 25,000 USD
  • 2nd Prize: 15,000 USD
  • 3rd Prize: 10,000 USD

International Judging Panel. The winners will be chosen by a judging panel made up of international representatives from the diabetes community and gain exposure internationally.

Invited VC Firms

Summit & Award Judging Criteria

The Summit is open to Patient Entrepreneurs developing big ideas using consumer, medical devices and healthcare IT that disrupt the future management of diabetes



You are eligible for the 2017 Lyfebulb-Novo Nordisk
Innovation Award if:

You work on innovative ideas and concepts for better management of diabetes using consumer or medical devices or healthcare IT (drug only innovations are excluded).

You live with diabetes or have a close relative and/or loved one with diabetes.

You have the aspiration to develop your project and to deliver the benefit to others suffering from the same burden.

You have a registered company for developing and commercializing your idea and concepts that the prize money can be award too.

You can document that there is a sound scientific and medical rationale for the idea.

You have a strong business case behind the idea.


The judging panel will look for evidence of:

Does the idea have potential to improve the lives of people with type 1 or type 2 diabetes?

In what aspect is the product/service unique in the market (not an altered marketed device) and does it meet other demands as well?

How is the idea truly disruptive for a different future for diabetes management?

Are the innovative and effective technologies scalable?

Ability to meet most of the healthcare related challenges (e.g. funding, regulations, requirements for clinical testing, etc.)

Team behind the project.

Achieving More, Together


Lyfebulb is a business focused on bridging patient communities with industry, and providing a strong voice to people living with chronic disease by empowering Patient Entrepreneurs. Our vision is to improve the quality of life of those living with diabetes and other chronic disease.

Lyfebulb was founded in 2014 and is headquartered in New York, NY.

Novo Nordisk

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity.

Headquartered in Denmark, Novo Nordisk employs approximately 42,000 people in 77 countries and markets its products in more than 165 countries.

For more information visit:, Facebook, Twitter, LinkedIn, YouTube